

In the Claims

Please make the following amendments in the claims:

Please cancel Claims 20-21 and 24-35 without prejudice to filing future continuing applications.

1-19. (canceled)

20. (canceled) ~~A method for promoting prolactin secretion in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 73, and~~

~~(ii) the amino acid sequence wherein the amino acid sequence represented by SEQ ID NO: 74 is added to the N terminus of the amino acid sequence represented by SEQ ID NO: 73, or a salt thereof to said mammal.~~

21. (canceled) ~~A method for promoting prolactin secretion in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~

~~(ii) the amino acid sequence represented by SEQ ID NO: 6,~~

~~(iii) the amino acid sequence represented by SEQ ID NO: 7,~~

~~(iv) the amino acid sequence represented by SEQ ID NO: 8,~~

~~(v) the amino acid sequence represented by SEQ ID NO: 47,~~

~~(vi) the amino acid sequence represented by SEQ ID NO: 48,~~

~~(vii) the amino acid sequence represented by SEQ ID NO: 49,~~

~~(viii) the amino acid sequence represented by SEQ ID NO: 50,~~

~~(ix) the amino acid sequence represented by SEQ ID NO: 61,~~
~~(x) the amino acid sequence represented by SEQ ID NO: 62,~~
~~(xi) the amino acid sequence represented by SEQ ID NO: 63, and~~
~~(xii) the amino acid sequence represented by SEQ ID NO: 64,~~
~~or a salt thereof to said mammal.~~

22. (amended) A method for promoting prolactin secretion in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence ~~selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~
~~(ii) the amino acid sequence represented by SEQ ID NO: 8,~~
~~(iii) the amino acid sequence represented by SEQ ID NO: 47, and~~
~~(iv) the amino acid sequence represented by SEQ ID NO: 61,~~
or a salt thereof to said mammal.

23. (amended) A method for promoting prolactin secretion in a mammal in need thereof, which comprises administering a pharmaceutical composition comprising a ligand polypeptide having an amino acid sequence ~~represented by~~ of SEQ ID NO: ~~61~~ 5, or a salt thereof, and a pharmaceutically acceptable carrier, excipient or diluent, to said mammal.

24. (canceled) ~~A method for promoting lactation in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 73, and~~

~~(ii) the amino acid sequence wherein the amino acid sequence represented by SEQ ID NO: 74 is added to the N-terminus of the amino acid sequence represented by SEQ ID NO: 73, or a salt thereof to said mammal.~~

~~25. (canceled) A method for promoting lactation in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~

~~(ii) the amino acid sequence represented by SEQ ID NO: 6,~~

~~(iii) the amino acid sequence represented by SEQ ID NO: 7,~~

~~(iv) the amino acid sequence represented by SEQ ID NO: 8,~~

~~(v) the amino acid sequence represented by SEQ ID NO: 47,~~

~~(vi) the amino acid sequence represented by SEQ ID NO: 48,~~

~~(vii) the amino acid sequence represented by SEQ ID NO: 49,~~

~~(viii) the amino acid sequence represented by SEQ ID NO: 50,~~

~~(ix) the amino acid sequence represented by SEQ ID NO: 61,~~

~~(x) the amino acid sequence represented by SEQ ID NO: 62,~~

~~(xi) the amino acid sequence represented by SEQ ID NO: 63, and~~

~~(xii) the amino acid sequence represented by SEQ ID NO: 64,~~

~~or a salt thereof to said mammal.~~

~~26. (canceled) A method for promoting lactation in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

- ~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~
- ~~(ii) the amino acid sequence represented by SEQ ID NO: 8,~~
- ~~(iii) the amino acid sequence represented by SEQ ID NO: 47, and~~
- ~~(iv) the amino acid sequence represented by SEQ ID NO: 61,~~

~~or a salt thereof to said mammal.~~

~~27. (canceled) A method for promoting lactation in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence represented by SEQ ID NO: 61, or a salt thereof to said mammal.~~

~~28. (canceled) A method for treating hypovarianism in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

- ~~(i) the amino acid sequence represented by SEQ ID NO: 73, and~~
- ~~(ii) the amino acid sequence wherein the amino acid sequence represented by SEQ ID NO: 74 is added to the N-terminus of the amino acid sequence represented by SEQ ID NO: 73, or a salt thereof to said mammal.~~

~~29. (canceled) A method for treating hypovarianism in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the~~

~~group consisting of~~

- ~~(i) the amino acid sequence represented by SEQ ID NO: 5;~~
 - ~~(ii) the amino acid sequence represented by SEQ ID NO: 6;~~
 - ~~(iii) the amino acid sequence represented by SEQ ID NO: 7;~~
 - ~~(iv) the amino acid sequence represented by SEQ ID NO: 8;~~
 - ~~(v) the amino acid sequence represented by SEQ ID NO: 47;~~
 - ~~(vi) the amino acid sequence represented by SEQ ID NO: 48;~~
 - ~~(vii) the amino acid sequence represented by SEQ ID NO: 49;~~
 - ~~(viii) the amino acid sequence represented by SEQ ID NO: 50;~~
 - ~~(ix) the amino acid sequence represented by SEQ ID NO: 61;~~
 - ~~(x) the amino acid sequence represented by SEQ ID NO: 62;~~
 - ~~(xi) the amino acid sequence represented by SEQ ID NO: 63, and~~
 - ~~(xii) the amino acid sequence represented by SEQ ID NO: 64;~~
- ~~or a salt thereof to said mammal.~~

~~30. (canceled) A method for treating hypoovarianism in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

- ~~(i) the amino acid sequence represented by SEQ ID NO: 5;~~
 - ~~(ii) the amino acid sequence represented by SEQ ID NO: 8;~~
 - ~~(iii) the amino acid sequence represented by SEQ ID NO: 47;~~
 - ~~(iv) the amino acid sequence represented by SEQ ID NO: 61, and~~
- ~~or a salt thereof to said mammal.~~

~~31. (canceled) A method for treating hypoovarianism in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence represented by SEQ ID NO: 61, or a salt thereof to said mammal.~~

~~32. (canceled) A method for eliciting an aphrodisiac effect in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 73, and~~

~~(ii) the amino acid sequence wherein the amino acid sequence represented by SEQ ID NO: 74 is added to the N-terminus of the amino acid sequence represented by SEQ ID NO: 73, or a salt thereof to said mammal.~~

~~33. (canceled) A method for eliciting an aphrodisiac effect in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~

~~(ii) the amino acid sequence represented by SEQ ID NO: 6,~~

~~(iii) the amino acid sequence represented by SEQ ID NO: 7,~~

~~(iv) the amino acid sequence represented by SEQ ID NO: 8,~~

~~(v) the amino acid sequence represented by SEQ ID NO: 47,~~

~~(vi) the amino acid sequence represented by SEQ ID NO: 48,~~

~~(vii) the amino acid sequence represented by SEQ ID NO: 49,~~

~~(viii) the amino acid sequence represented by SEQ ID NO: 50,~~

~~(ix) the amino acid sequence represented by SEQ ID NO: 61,~~

~~(x) the amino acid sequence represented by SEQ ID NO: 62,~~
~~(xi) the amino acid sequence represented by SEQ ID NO: 63, and~~
~~(xii) the amino acid sequence represented by SEQ ID NO: 64,~~
~~or a salt thereof to said mammal.~~

~~34. (canceled) A method for eliciting an aphrodisiac effect in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence selected from the group consisting of~~

~~(i) the amino acid sequence represented by SEQ ID NO: 5,~~
~~(ii) the amino acid sequence represented by SEQ ID NO: 8,~~
~~(iii) the amino acid sequence represented by SEQ ID NO: 47,~~
~~(iv) the amino acid sequence represented by SEQ ID NO: 61, and~~
~~or a salt thereof to said mammal.~~

~~35. (canceled) A method for eliciting an aphrodisiac effect in a mammal in need thereof, which comprises administering a ligand polypeptide having an amino acid sequence represented by SEQ ID NO: 61, or a salt thereof to said mammal.~~